
Opinion|Videos|January 9, 2025
CARTITUDE-4: Latest Data of Cilta-Cel for Early R/R MM
Author(s)Aimee Merino, MD
Aimee Merino, MD, discusses how the latest efficacy outcomes from the CARTITUDE-4 trial, evaluating ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma, have influenced her approach to patient selection and referral for chimeric antigen receptor T-cell therapy in early relapse cases.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please briefly discuss the latest efficacy outcomes from the CARTITUDE-4 trial, evaluating ciltacabtagene autoleucel in patients with relapsed refractory multiple myeloma (R/R MM).
- How have the latest findings informed your approach to patient selection and referral for chimeric antigen receptor T-cell therapy in early R/R MM?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5































